Drug Trial Radar · NCT02028780
Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BI 655075 (Idarucizumab) Administered Alone or With Dabigatran Etexilate in Japanese Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Feb 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Jan 2014
Primary completion
Aug 2014
Study completion Aug 2014
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective is to investigate the safety, tolerability and pharmacokinetics of BI 655075 following intravenous administration of single rising doses of BI 655075 when administered alone and after administration of dabigatran.
Conditions
- Healthy
Interventions
Placebo to doseDrug
placebo
IdarucizumabDrug
short infusion
Placebo to IdarucizumabDrug
Placebo to Idarucizumab
dabigatranDrug
2 capsules dabigatran
IdarucizumabDrug
short infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Drug-related Adverse Events in Part 1 and Part 2Time frame: From first drug administration until 13 weeks after the last drug administration, upto 98 days (Part-I) & upto 108 days (Part-II)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
1321.5.00001 Boehringer Ingelheim Investigational Site
Sumida-ku, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.